Dementia Alzheimer's Type Clinical Trial
Official title:
A Study Examining the Safety and Activity of Innate Immune System Stimulation With Leukine® (Sargramostim) to Reduce Brain Amyloid Load in Patients With Mild Cognitive Impairment Due to Alzheimer's Disease
Primary Objective:
To compare the effect of repeat doses of Leukine to placebo administered subcutaneously (SC)
on established cortical amyloid load in patients with mild cognitive impairment (MCI) due to
Alzheimer's disease (AD).
Secondary Objective:
- To evaluate safety and tolerability of Leukine versus placebo.
- To explore the effect of Leukine versus placebo on cognitive performance.
- To collect biospecimens for future biomarker research.
The total duration of study period per patient is up to 28 weeks. ;
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Completed |
NCT01266525 -
Effect of Different Doses of SAR110894 on Cognition in Patients With Mild to Moderate Alzheimer's Disease on Donepezil
|
Phase 2 |